- Home
- KPRX vs BFRI Comparison
KPRX vs BFRI Comparison
Compare KPRX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- BFRI
- Stock Information
- Founded
- KPRX 1998
- BFRI 1997
- Country
- KPRX United States
- BFRI United States
- Employees
- KPRX N/A
- BFRI N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- BFRI Health Care
- Exchange
- KPRX Nasdaq
- BFRI Nasdaq
- Market Cap
- KPRX 8.6M
- BFRI 7.9M
- IPO Year
- KPRX N/A
- BFRI 2021
- Fundamental
- Price
- KPRX $2.99
- BFRI $1.06
- Analyst Decision
- KPRX Strong Buy
- BFRI Strong Buy
- Analyst Count
- KPRX 1
- BFRI 1
- Target Price
- KPRX $10.00
- BFRI $2.75
- AVG Volume (30 Days)
- KPRX 62.4K
- BFRI 236.9K
- Earning Date
- KPRX 08-08-2025
- BFRI 08-13-2025
- Dividend Yield
- KPRX N/A
- BFRI N/A
- EPS Growth
- KPRX N/A
- BFRI N/A
- EPS
- KPRX N/A
- BFRI N/A
- Revenue
- KPRX $20,000.00
- BFRI $37,997,000.00
- Revenue This Year
- KPRX N/A
- BFRI $11.75
- Revenue Next Year
- KPRX N/A
- BFRI $17.09
- P/E Ratio
- KPRX N/A
- BFRI N/A
- Revenue Growth
- KPRX N/A
- BFRI 14.28
- 52 Week Low
- KPRX $2.51
- BFRI $0.54
- 52 Week High
- KPRX $4.80
- BFRI $2.22
- Technical
- Relative Strength Index (RSI)
- KPRX 47.28
- BFRI 74.96
- Support Level
- KPRX $2.96
- BFRI $0.79
- Resistance Level
- KPRX $3.29
- BFRI $1.17
- Average True Range (ATR)
- KPRX 0.15
- BFRI 0.10
- MACD
- KPRX 0.01
- BFRI 0.03
- Stochastic Oscillator
- KPRX 38.78
- BFRI 77.91
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.